Prediction of Methotrexate Clinical Response in Portuguese Rheumatoid Arthritis Patients: Implication of MTHFR rs1801133 and ATIC rs4673993 Polymorphisms
Table 3
Relation between genetic variables and clinical response to methotrexate.
Response ()
Nonresponse ()
value
OR (95% CI)
MTHFR C677T, rs1801133
CC
52 (49.5)
53 (50.5)
Reference
CT
46 (46.5)
53 (53.5)
0.662
1.13 (0.65–1.96)
TT
7 (24.1)
22 (75.9)
0.015
3.08 (1.21–7.84)
CC
52 (49.5)
53 (50.5)
Reference
T carrier
53 (41.4)
75 (58.6)
0.215
1.39 (0.83–2.33)
C carrier
98 (48.0)
106 (52.0)
Reference
TT
7 (24.1)
22 (75.9)
0.015
2.91 (1.19–7.10)
ATIC T675C, rs4673993
TT
48 (43.6)
62 (56.4)
Reference
TC
40 (40.4)
59 (59.6)
0.637
1.14 (0.66–1.98)
CC
17 (70.8)
7 (29.2)
0.016
0.32 (0.12–0.83)
TT
48 (43.6)
62 (56.4)
Reference
C carrier
57 (46.3)
66 (53.7)
0.679
0.90 (0.53–1.50)
T carrier
88 (42.1)
121 (57.9)
Reference
CC
17 (70.8)
7 (29.2)
0.007
0.30 (0.12–0.75)
Results are expressed in (%). value < 0.05 is considered to be of statistical significance (highlighted in bold). ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; C: cytosine; CI: confidence interval; MTHFR: methylenetetrahydrofolate reductase; OR: odds ratio; T: thymine.
